NCT04380181

Brief Summary

Our study is based on the observation that management of the cardiopulmonary by-pass withdrawal in pediatric heart surgery is quite variable between medical teams. Indeed, in our center (HUDERF), the most common inotropic plan is dobutamine only or combination of milrinone and adrenalin but their uses seem to be very anesthesiologist dependent. Despite the lack of sufficient evidence, the choice is probably multi-factorial, based mainly on the inotrope pharmacology, the patient physiopathology and the anesthesiologist preference. The aim of this study is to determine if one of these inotropic strategy (dobutamine VS milrinone + adrenaline) is better compared to the other in terms of morbi-mortality. In order to do that, the investigators will realize a retrospective study based on files from January 2008 to December 2018 concerning 250 selected patients.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
250

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 5, 2020

Completed
3 days until next milestone

First Posted

Study publicly available on registry

May 8, 2020

Completed
3 days until next milestone

Study Start

First participant enrolled

May 11, 2020

Completed
25 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 5, 2020

Completed
5 days until next milestone

Study Completion

Last participant's last visit for all outcomes

June 10, 2020

Completed
Last Updated

June 11, 2020

Status Verified

June 1, 2020

Enrollment Period

25 days

First QC Date

May 5, 2020

Last Update Submit

June 10, 2020

Conditions

Keywords

pediatric cardiopulmonary bypassmilrinonedobutamineepinephrine

Outcome Measures

Primary Outcomes (1)

  • MODS2 score

    Impact of the inotropic plan on the morbi-mortality. Use of the MODS2 score who is defined by death or 2 organ's failures: circulation, respiratory or renal

    Weaning from cardiopulmonary bypass in the operating room

Study Arms (2)

Dobutamine

Weaning from cardiopulmonary bypass using dobutamine as inotrope.

Drug: dobu

Milrinone-epinephrine

Weaning from cardiopulmonary bypass using milrinone and epinephrine as inotropes.

Interventions

dobuDRUG

Use of dobutamine versus milrinone and epinephrine for separation from cardiopulmonary bypass

Also known as: milrinone-epinephrine
Dobutamine

Eligibility Criteria

AgeUp to 1 Year
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

Children under 1 year undergoing complex cardiac surgery with cardiopulmonary bypass

You may qualify if:

  • Patient under 1 year old. Cardiac surgery with CPB between 2008-2018. RACHS-1 risk categories \>3.
  • We selected the most relevant and common surgery in our center:
  • Transposition of the great arteries
  • Atrio-ventricular canal defect
  • Aortic coarctation or interruption
  • Truncus arteriosus
  • Mitral valvuloplasty

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hôpital Universitaire des Enfants Reine Fabiola

Brussels, 1020, Belgium

Location

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head, Anesthesiology

Study Record Dates

First Submitted

May 5, 2020

First Posted

May 8, 2020

Study Start

May 11, 2020

Primary Completion

June 5, 2020

Study Completion

June 10, 2020

Last Updated

June 11, 2020

Record last verified: 2020-06

Data Sharing

IPD Sharing
Will not share

Locations